Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Aug 16, 2022 10:12am
193 Views
Post# 34899110

RE:Financing

RE:FinancingThanks for your contribution Quacker and welcome to the discussion amongst real shareholders.  Your suggestion for requesting Baxter to accelerate a payment (or do an advance against the next one) is soundly based.  Spectral has initiated the EDEN study at Baxter's request and also initiated pre-marketing efforts - Baxter is responsible for all costs of marketing don't forget - so asking for a contribution to the corporate kitty is a very reasonable request.  Hopefully the brainiacs in charge can see what is right in front of their eyes for liquidity purposes.  No friends and family party favors necessary if the obvious option is chosen.

I support your suggestions for giving us some representation on the board especially since 30% did not support Seto being appointed to the Board.  But I expect the insiders would not want the "outside" shareholders having their input in matters of fiduciary duties and fair compensation policies.
<< Previous
Bullboard Posts
Next >>